Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410020 | 0.85 | USP30 (0.42) | NR1H2NR1H3 | |
| SCHEMBL4916393 | 0.85 | USP30 (0.42) | NR1H2NR1H3 | |
| SCHEMBL4916392 | 0.85 | USP30 (0.42) | NR1H2NR1H3 | |
| SCHEMBL14224497 | 0.83 | HSD17B10 (0.45) | NR1H2HPGDPREPNR1H3SMN1; SMN2 | |
| SCHEMBL14224498 | 0.83 | HSD17B10 (0.45) | NR1H2HPGDPREPNR1H3SMN1; SMN2 | |
| SCHEMBL254261 | 0.83 | HSD17B10 (0.45) | NR1H2HPGDPREPNR1H3SMN1; SMN2 | |
| SCHEMBL6787947 | 0.82 | USP2 (0.41) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL14805847 | 0.81 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL3572552 | 0.80 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL3572550 | 0.80 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9481675-B2 | Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20130079323-A1 | GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037059-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | NR1H2 701/4885CHRM2 1809/4885CHRM1 1284/4885 |
| US-20130079323-A1 | GYRASE INHIBITORS | TOP1, CA7, TOP2B | NR1H2 701/4885CHRM2 1809/4885CHRM1 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.